bioRxivImmunology
Augmenting CAR NK cell Anti-tumor Activity by Synapse Tuning
P. Chockley, J. Ibanez, G. Krenciute, L. Talbot, S. Gottschalk
Abstract
Introductory ParagraphChimeric antigen receptor (CAR) technologies have been clinically implemented for the treatment of hematological malignancies; however, solid tumors remain resilient to CAR therapeutics1-3. Natural Killer (NK) cells may provide an optimal class of immune cells for CAR-based approaches due to their inherent anti-tumor functionality. We sought to tune CAR synapses in NK cells by adding an intracellular scaffolding protein binding site to the CAR. We employed a PDZ binding motif (PDZbm) that specifically binds Scribble4 resulting in additional scaffolding crosslinking to enhance synapse formation and cell polarization5,6. Combined effects of this novel CAR design resulted in increased effector cell functionality in vitro and in vivo. Synapse-tuned CAR-NK cells exhibited amplified synaptic strength, number and abundance of secreted cytokines, enhanced killing of tumor cells, and prolonged survival with tumor clearance in two solid tumor models. Thus, synapse tuning has the potential to improve the efficacy of CAR-based cell therapeutics.
- organism: human
- assay: CITE-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor control
W. Sam Nutt, Mitchell G. Kluesner, … Shivani Srivastava·bioRxiv·Dec 15, 2025
- Chimeric Antigen Cytotoxic Receptors for In-Vivo Engineering of Tumor-targeting Natural Killer Cells
N. Diwanji, D. Getts, Y. Wang·bioRxiv·Nov 7, 2023
- Engineered NKG2C+ NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome
Kyle B. Lupo, M. Kazim Panjwani, … Katharine C. Hsu·Journal of Clinical InvestigationPeer-reviewed·Oct 20, 2026
- CTLA-4 tail fusion enhances CAR-T anti-tumor immunity
- Evaluation of natural killer cell tumor homing and effector function in response to CDK4/6 and AURKA inhibition in a melanoma tumor-on-a-chip platform
Srija Chakraborty, Connor Durham, … Aleksander Skardal·bioRxiv·Jul 9, 2025
- JNK knockdown enhances CAR-T cell cytotoxicity
Charles J. Kuhlmann, Chloe E Jepson, … Masakazu Kamata·bioRxiv·Aug 14, 2025